French biopharmaceutical company Poxel SA (Euronext:POXEL) reported on Thursday the submission of a Japanese New Drug Application (J-NDA) for its lead product, Imeglimin.
Poxel's Japanese partner, Sumitomo Dainippon Pharma, submitted the application to the Pharmaceuticals and Medical Devices Agency (PMDA) seeking approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes.
The Imeglimin J-NDA is supported by preclinical and clinical trials, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) project in Japan which included three pivotal trials to evaluate Imeglimin's efficacy and safety in over 1,100 patients. In all three trials, Imeglimin met its primary endpoints and objectives and was observed to exhibit a favourable safety and tolerability profile, the company said.
Thomas Kuhn, CEO of Poxel, said that the J-NDA submission represents a "significant milestone" for the company and the culmination of several years of clinical development work.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study